Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab

被引：27

作者：

Fink, A. M. ^{[1
,2
,15
,16
]}

Bottcher, S. ^{[3
,15
,16
]}

Ritgen, M. ^{[3
]}

Fischer, K. ^{[1
,2
]}

Pflug, N. ^{[1
,2
]}

Eichhorst, B. ^{[1
,2
]}

Wendtner, C-M ^{[1
,2
]}

Winkler, D. ^{[4
]}

Buhler, A. ^{[4
]}

Zenz, T. ^{[4
,5
,6
,7
]}

Staib, P. ^{[8
]}

Mayer, J. ^{[9
,10
,11
]}

Hensel, M. ^{[5
,6
,7
]}

Hopfinger, G. ^{[12
]}

Wenger, M. ^{[13
]}

Fingerle-Rowson, G. ^{[1
,2
]}

Dohner, H. ^{[4
]}

Kneba, M. ^{[3
]}

Stilgenbauer, S. ^{[4
]}

Busch, R. ^{[14
]}

Hallek, M. ^{[1
,2
]}

机构：

[1] Dept Internal Med 1, Cologne, Germany

[2] Ctr Integrated Oncol Cologne Bonn, Cologne, Germany

[3] Univ Hosp Schleswig Holstein, Dept Med 2, Kiel, Germany

[4] Klinikum Munchen Schwabing, Munich, Germany

[5] Univ Ulm, Dept Internal Med 3, Ulm, Germany

[6] Natl Ctr Tumor Dis NCT, Dept Translat Oncol, Heidelberg, Germany

[7] German Canc Res Ctr, Heidelberg, Germany

[8] Heidelberg Univ, Dept Med 5, Heidelberg, Germany

[9] St Antonius Hosp Eschweiler, Klin Hamatol & Onkol, Eschweiler, Germany

[10] Univ Hosp Brno, Dept Internal Med Hematol & Oncol, Brno, Czech Republic

[11] Masaryk Univ, CEITEC, Brno, Czech Republic

[12] Mannheimer Onkol Praxis, Mannheim, Germany

[13] Hanusch Hosp Vienna, Dept Med 3, Vienna, Austria

[14] Paracelsus Med Univ, Dept Med 3, Salzburg, Austria

[15] F Hoffmann Roche Ltd, Pharmaceut Div, Basel, Switzerland

[16] Tech Univ, Inst Med Stat & Epidemiol, Munich, Germany

来源：

LEUKEMIA | 2013年 / 27卷 / 09期

关键词：

CHRONIC LYMPHOCYTIC-LEUKEMIA; SURVIVAL; QUANTIFICATION; PROGRESSION;

D O I：

10.1038/leu.2013.190

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1949 / +

页数：5

共 50 条

[41] Factors influencing First-Line Treatment in CLL
Dilhuydy, Marie-Sarah
HEMATOLOGIE, 2024, 30 : 13 - 18
[42] Ibrutinib and Venetoclax for First-Line Treatment of CLL
Kater, Arnon P.
Levin, Mark-David
Niemann, Carsten U.
NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (08): : 788 - 789
[43] The treatment of complicated and high risk chronic lymphocytic leukemia (CLL) with fludarabine, cyclophosphamide and rituximab (FCR).
Donthireddy, V
Shurafa, MS
Saleh, M
Kamboj, G
Wang, D
Janakiraman, N
BLOOD, 2005, 106 (11) : 341B - 341B
[44] First-line therapy for young patients with CLL
Jain, Nitin
O'Brien, Susan
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2016, : 146 - 148
[45] First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial
Eichhorst, Barbara
Fink, Anna-Maria
Bahlo, Jasmin
Busch, Raymonde
Kovacs, Gabor
Maurer, Christian
Lange, Elisabeth
Koeppler, Hubert
Kiehl, Michael
Soekler, Martin
Schlag, Rudolf
Vehling-Kaiser, Ursula
Koechling, Georg
Ploeger, Christoph
Gregor, Michael
Plesner, Torben
Trneny, Marek
Fischer, Kirsten
Doehner, Harmut
Kneba, Michael
Wendtner, Clemens-Martin
Klapper, Wolfram
Kreuzer, Karl-Anton
Stilgenbauer, Stephan
Boettcher, Sebastian
Hallek, Michael
LANCET ONCOLOGY, 2016, 17 (07): : 928 - 942
[46] Early analysis of combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab for relapsed and refractory patients with CLL.
Wierda, W
O'Brien, S
Ferrajoli, A
Faderl, S
Kornblau, SM
Andreef, M
Koller, C
Garcia-Manero, G
Thomas, D
Kantarjian, H
Keating, M
BLOOD, 2003, 102 (11) : 360B - 360B
[47] Rituximab as a first-line agent for the treatment of dermatomyositis
Haroon, Muhammad
Devlin, Joe
RHEUMATOLOGY INTERNATIONAL, 2012, 32 (06) : 1783 - 1784
[48] Rituximab in Membranous Nephropathy: Is It a First-Line Treatment?
Appel, Gerald B.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2012, 23 (08): : 1280 - 1282
[49] Rituximab as a first-line agent for the treatment of dermatomyositis
Muhammad Haroon
Joe Devlin
Rheumatology International, 2012, 32 : 1783 - 1784
[50] Fludarabine, cyclophosphamide and rituximab up to four courses as first line treatment for indolent non-hodgkin lymphomas
Falantes, J. F.
Ríos Herranz, E.
Marin Niebla, A.
Martino Galiana, M. L.
Parody, R.
Blas Orlando, J. M.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 403 - 403

← 1 2 3 4 5 →